The 30th National High School Manga Championship (Manga Koshien)
19.7.2021 08:30:00 EEST | Business Wire | Press release
Manga Koshien is a competition where high school students compete for the position of Number 1 by creating one-page manga since 1992.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210718005034/en/
poster (Graphic: Business Wire)
About 300 high school teams, comprising three to five students each, enter every year. Of these, 30 teams are selected to go on to the championship round in August. Competing teams battle it out with their ideas, techniques and teamwork, all within a limited amount of time.
Talented students participating in the main round may also be scouted by major manga publishers and perhaps even debut as professionals!
[ The 30th Manga Koshien ]
As this year’s tournament is celebrating the 30th anniversary of our event, we will advance a total of 40 teams, 10 more than usual, to the final.
There are various events by professional manga artists between the competitions, and it will be a spectacular delivery. Please take a look.
- Semifinal round: August 6th (Fri)
- The final round: August 7th (Sat)
- URL: https://mangaoukoku-tosa.jp/manga-koshien30
[ Manga Koshien Gokko ]
An online contest for high school individual students or teams from all over the world who could not participate in the Manga Koshien Finals.
- Work theme: “30” (Free theme as long as “30” is related to the content or visual elements)
- Eligibility for submission: Students whose school level is equivalent to that of high schools in Japan.
- Judging: Submitted works will be displayed on a public website and subject to general voting.
The number of votes cast in the general vote determines the results from 1st to 3rd place.
-
Supplementary prize:
1st place: Wacom Cintiq 16, CLIP STUDIO PAINT EX 2 (Device Plan 2 Year Edition), Sleeping Cat plush toy (big size)
2nd place: CLIP STUDIO PAINT PRO (2 device plan, 2 year subscription), Sleeping Cat plush toy (middle size)
3rd place: CLIP STUDIO TABMATE, Sleeping Cat plush toy (small size)
- Submission period: July 17th (Sat) 0:00 to August 6th (Fri) 16:00 (JST)
- Voting period: July 17th (Sat) 0:00 to August 7th (Sat) 15:00 (JST)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210718005034/en/
Contact information
For Enquiries
Manga Kingdom Tosa Promotion Division, Department of Culture, Community, and Sports, Kochi Prefecture
Email: 141701@ken.pref.kochi.lg.jp
Manga Kingdom Tosa Promotional Committee
Enquiries Regarding this press release
In-Charge: Yasuaki Okamatsu and Maya Nakahira
Manga Kingdom Tosa Promotion Division, Department of Culture, Community, and Sports, Kochi Prefecture
Tel: +81-88-823-9711
Fax: +81-88-823-9296
Email: 141701@ken.pref.kochi.lg.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 15:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. The oral presentation of these data is taking place at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29 – June 2, 2026, in Chicago (Abstract #LBA7000. Session: Oral Abstract Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia. May 30, 4:00 – 7:00 p.m. ET [3:00 – 6:00 p.m.
Fortegra Completes Acquisition by DB Insurance29.5.2026 23:30:00 EEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 23:01:00 EEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom